News
ABEO
7.38
-0.34%
-0.03
Weekly Report: what happened at ABEO last week (0803-0807)?
Weekly Report · 2d ago
Abeona’s New Phase 4 Wound Study: What ABEO Investors Should Watch
TipRanks · 5d ago
Abeona Therapeutics: CMS Reimbursement Catalyst Supports ZEVASKYN Uptake and Unchanged $20 Price Target
TipRanks · 08/05 10:26
Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule
Benzinga · 08/04 11:37
Weekly Report: what happened at ABEO last week (0727-0731)?
Weekly Report · 08/03 09:18
Weekly Report: what happened at ABEO last week (0720-0724)?
Weekly Report · 07/27 09:19
Abeona Therapeutics activates Cincinnati Children’s as treatment center
TipRanks · 07/21 13:25
Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa
Benzinga · 07/21 11:37
Weekly Report: what happened at ABEO last week (0713-0717)?
Weekly Report · 07/20 09:18
Weekly Report: what happened at ABEO last week (0706-0710)?
Weekly Report · 07/13 09:18
Arqit, American Eagle, Abeona, Vipshop, Verisign Shake-Up
TipRanks · 07/11 13:01
Abeona Therapeutics Executives Make Bold Moves With Fresh Insider Stock Sales
TipRanks · 07/10 02:00
Weekly Report: what happened at ABEO last week (0629-0703)?
Weekly Report · 07/06 09:19
Abeona Therapeutics Insider Move Sparks Fresh Interest From Investors
TipRanks · 07/03 02:04
Weekly Report: what happened at ABEO last week (0622-0626)?
Weekly Report · 06/29 09:18
Weekly Report: what happened at ABEO last week (0615-0619)?
Weekly Report · 06/22 09:20
Abeona Therapeutics Rocked by Major Insider Stock Sale
TipRanks · 06/16 02:03
Weekly Report: what happened at ABEO last week (0608-0612)?
Weekly Report · 06/15 09:20
Abeona Shareholders Back Board, Equity Plan at Meeting
TipRanks · 06/12 23:03
Abeona Therapeutics announces resignation of board member
TipRanks · 06/12 12:01
More
Webull provides a variety of real-time ABEO stock news. You can receive the latest news about Abeona Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).